A Modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR 2/2 mouse model

African horse sickness (AHS) is a lethal viral disease of equids, which is transmitted by Culicoides midges that become infected after biting a viraemic host. The use of live attenuated vaccines has been vital for the control of this disease in endemic regions. However, there are safety concerns over their use in non-endemic countries. Research efforts over the last two decades have therefore focused on developing alternative vaccines based on recombinant baculovirus or live viral vectors expressing structural components of the AHS virion. However, ethical and financial considerations, relating to the use of infected horses in high biosecurity installations, have made progress very slow. We have therefore assessed the potential of an experimental mouse-model for AHSV infection for vaccine and immunology research. We initially characterised AHSV infection in this model, then tested the protective efficacy of a recombinant vaccine based on modified vaccinia Ankara expressing AHS-4 VP2 (MVA-VP2). © 2011 Castillo-Olivares et al.

Bibliographic Details

Main Authors:	Castillo-Olivares, J., Calvo Pinilla, Eva María, Casanova, I., Bachanek-Bankowska, K., Chiam, R., Maan, S., Nieto, J. M., Ortego Alonso, Francisco Javier, Mertens, P. P. C.
Format:	artículo biblioteca
Language:	English
Published:	Public Library of Science 2011
Online Access:	http://hdl.handle.net/20.500.12792/5807 http://hdl.handle.net/10261/292380
Tags:	Add Tag No Tags, Be the first to tag this record!